What Happened?
Seattle, AB-based Avalyn-Pharma Appointed Bruce Montgomery as Chief Executive Officer
About the Company
Avalyn is a biopharma company committed to developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. Our lead asset is inhaled pirfenidone (AP01) for the treatment of IPF. With offices in Seattle and San Diego, Avalyn`s experienced clinical and inhaled product development team is rapidly advancing AP01 for the treatment of IPF and additional pipeline candidates for IPF and other severe respiratory diseases.
About the Person
Bruce Montgomery is Chief Executive Officer at Avalyn Pharma. Previously, Bruce held various senior HR leadership roles in the industry.
Info Source
News
Short Profile